Biotechnology Company Deals With Other Biotechnology Companies: Nov. 1 - Dec. 20, 2012

(BioWorld Insight Via Acquire Media NewsEdge) Total Value in 2012: $7,093.35M* Number of Deals in 2012: 239 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date NOVEMBER Ablynx NV (Ghent, Belgium) Algeta ASA (Oslo, Norway) ND Research collaboration to evaluate a targeted thorium conjugate by combining Algeta's thorium-227 alpha-pharmaceutical payload with nanobodies generated by Ablynx Ablynx will provide access to nanobodies against a specific, undisclosed target and Algeta will provide access to chelation and conjugation technologies, as well as to its alpha-emitter thorium-227 11/26/12 BiOasis Technologies Inc. (Vancouver, British Columbia) MedImmune Inc.(Gaithersburg, Md.) ND Research and evaluation agreement under which BiOasis will conduct certain experiments at MedImmune's expense with the objective of demonstrating that BiOasis's Transcend technology can deliver to the brain compounds of interest to MedImmune Financial terms were not disclosed.

11/15/12 BiondVax Pharmaceuticals Ltd. (Nes Ziona, Israel) MonoSol Rx LLC (Warren, N.J.) ND Partnership to develop an oral film formulation of BiondVax's universal flu vaccine, M001, using MonoSol Rx's PharmFilm delivery platform Financial terms were not disclosed 11/8/12 BioTime Inc. (Alameda, Calif.) and subsidiary BioTime Acquisition Corp.

Geron Corp.(Menlo Park, Calif.) $10 Companies entered a nonbinding letter of intent for a $10M investment from a private investor to provide financing for a proposed acquisition of stem cell assets from Geron The investor will invest $5M in BioTime by purchasing 1.35M shares, priced at about $3.70 apiece, and warrants to purchase 650,000 additional shares; the investor also will contribute $5M in cash to BAC in exchange for shares of BAC common stock, plus warrants to buy an additional 350,000 shares; Geron stockholders will receive shares representing about 21.4% of the common stock of BAC, as well as warrants to purchase 8M shares; BioTime will hold about 71.6% of BAC, while the private investor will hold about 7% 11/19/12 Catalyst Pharmaceutical Partners Inc.(Coral Gables, Fla.) BioMarin Pharmaceuticals Inc. (Novato, Calif.) $5 Sublicensing agreement for rights to Firdapse, a drug in development for Lambert-Eaton myasthenic syndrome BioMarin agreed to invest $5M in Catalyst under a promissory note and note purchase agreement 11/1/12 Colby Pharmaceutical Co. (San Jose, Calif.) MannKind Corp.(Valencia, Calif.) $140 Deal for disease-specific antigen compounds and intra-lymph node injection (INLI) technologies from its MKC1106 cancer vaccine program Colby is paying up to $140M in up-front and milestone payments to MannKind, which also will receive tiered royalties on product sales 11/14/12 Crystal Bioscience Inc. (Emeryville, Calif.) Integral Molecular Inc. (Philadelphia) ND Research collaboration to generate panels of chicken monoclonal antibodies against undisclosed therapeutic G protein-coupled receptor and ion channel targets The collaboration will combine Integral's Lipoparticle platform for immunization with native conformation multispanning membrane proteins with Crystal's GEM technology for the recovery of monoclonal antibodies against otherwise conserved proteins raised in immunized chickens 11/16/12 Curie-Cancer (Paris) Harmonic Pharma (Villers les Nancy, France) ND Collaboration aimed at exploring the anticancer activity of several molecules Financial terms were not disclosed 11/6/12 Curis Inc. (Lexington, Mass.) Genentech Inc.(South San Francisco) $9.5 Licensing agreement for a Phase II-ready apoptosis promoter Curis is spending $9.5M on the license, gaining worldwide rights to the oncology candidate, GDC-0917 11/29/12 Cytovance Biologics Inc. (Oklahoma City) Fountain BioPharma Inc.(Taiwan) ND Biopharmaceutical development and manufacturing collaboration for FB301, a monoclonal antibody under development for allergic disease Cytovance will conduct cell line generation, cell culture process optimization, recovery and purification development, cGMP manufacturing and technical and regulatory support 11/1/12 Erytech Pharma (Lyon, France) Orphan Europe (Part of Recordati Group; Milano, Italy) ND Entered a definitive agreement granting exclusive rights for the commercialization and distribution of Graspa in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in Europe Graspa, L-asparaginase encapsulated in human erythrocytes, is in a pivotal Phase II/III trial in ALL and is slated to start a Phase IIb study in AML in Europe 11/27/12 Evotec AG (Hamburg, Germany) Haplogen GmbH (Vienna, Austria) ND Collaboration agreement to discover and develop small molecules against viral infectious diseases The two companies will develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell, discovered by Haplogen 11/16/12 Evotec AG (Hamburg, Germany) Probiodrug AG (Halle, Germany) ND Evotec will set up and validate assays to support the preclinical and clinical development of glutaminyl cyclase inhibitors for the treatment of Alzheimer's disease Glutaminyl cyclase is an enzyme target discovered and validated by Probiodrug which plays a crucial role in the pathogenesis of the condition as well as potentially other diseases 11/29/12 Foundation Medicine Inc. (Cambridge, Mass.) Ariad Pharmaceuticals Inc. (Cambridge, Mass.) ND Genomic profiling collaboration to study AP26113, Ariad's investigational dual-inhibitor of ALK and EGFR in patients with non-small-cell lung and other cancers Foundation Medicine will generate genomic profile information for patients enrolled in Ariad's ongoing Phase I/II trial, and those data will be matched with clinical observations to understand the activity and selectivity profile of AP26113 11/14/12 ImmunGene Inc. (Thousand Oaks, Calif.) Caliber Biotherapeutics LLC (Bryan, Texas) ND Companies launched Valor Biotherapeutics LLC, a joint venture designed to develop and commercialize monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting certain cancers ImmunGene will grant Valor exclusive licenses to its IP for three mAb-IFN fusion product candidates currently in various stages of preclinical development; Caliber will provide funding to enable Valor to reach undisclosed development milestones for the compounds in non-Hodgkin's lymphoma, multiple myeloma and breast cancer 11/16/12 NanoViricides Inc. (West Haven, Conn.) Bioanalytical Systems Inc. (West Lafayette, Ind.) ND Deal to conduct drug development studies required to submit investigational new drug applications to the FDA for its nanoviricides drug candidates Safety pharmacology studies also will be conducted to assess the effects of FluCide on the cardiovascular, respiratory and central nervous systems 11/14/12 Synthetic Biologics Inc. (Rockville, Md.) Prev AbR LLC ND Agreement to acquire Prev AbR's clinical-stage and related beta-lactamase assets targeted for the prevention of Clostridium difficile infection The acquisition includes the clinical-stage and related beta-lactamase assets, P1A, P2A and P3A (now known as SYN-004) and manufacturing process data and all issued and pending U.S. and international patents intended to support an IND and biologic license application with the FDA 11/13/12 Tekmira Pharmaceuticals Corp. (Vancouver, British Columbia) Marina Biotech Inc. (Bothell, Wash.) ND Worldwide, nonexclusive license agreement for an RNAi payload technology called Unlocked Nucleobase Analog (UNA) Marina will get an up-front payment plus milestone and royalty payments on products developed by Tekmira using the UNA technology 11/30/12 Unigene Laboratories Inc. (Boonton, N.J.) Tarix Pharmaceuticals Ltd. (Cambridge, Mass.) ND Agreement to develop oral TXA127, Tarix's lead peptide drug candidate Under the agreement, Tarix will gain exclusive, worldwide rights to peptelligence for use with angiotensin and its functional equivalents, analogues or derivatives; in exchange, Tarix will pay a percentage of sales revenues; there is no up-front payment 11/28/12 DECEMBER BiOasis Technologies Inc. (Vancouver, British Columbia) UCB SA (Brussels, Belgium) ND Deal to evaluate the application of BiOasis' technology for drug delivery to the brain BiOasis will carry out studies of the technology as it relates to UCB's central nervous system compounds 12/4/12 Biogen Idec Inc. (Weston, Mass.) Isis Pharmaceuticals Inc. (Carlsbad, Calif.) $200 Partnership to discover and develop antisense drugs for several undisclosed targets in the area of neurological and neuromuscular disorders Biogen Idec will pay Isis $30M up front to discover a lead candidate for each of three targets, and Isis will be eligible for milestone payments; Biogen Idec also has an option to license a drug from each of those three programs through completion of Phase II trials; payments to Isis could total $200 million, including license fees and regulatory milestones per program, plus additional double-digit royalties 12/11/12 BrainStorm Cell Therapeutics Inc. (New York) Octane Biotech (Kingston, Ontario) ND Deal to jointly develop a bioreactor for production of its NurOwn stem cell therapy candidate The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, and the project is supported by a grant from the Canada-Israel Industrial Research and Development Foundation 12/18/12 Galena Biopharma Inc. (Lake Oswego, Ore.) Leica Biosystems (Newcastle-Upon-Tyne, UK) ND Partnership to develop a companion diagnostic for Galena's NeuVax (nelipepimut-S or E75) breast cancer therapeutic Leica's Bond Oracle HER2 IHC System companion diagnostic will be used to support the selection of the appropriate patients for the NeuVax Phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment) study 12/7/12 Genovax srl (Colleretto Giacosa, Italy) Mediolanum Farmaceutici SpA (Milan, Italy) ND Mediolanum acquired rights to GX301, a cancer vaccine, from Genovax Mediolanum will take over further development and commercialization of the drug, with support from Genovax, in exchange for up-front and milestone payments, plus royalties.

12/4/12 H3 Biomedicine Inc. (Cambridge, Mass.) Sage Bionetworks (Seattle) ND Partnership to develop software platforms for cancer genomics research Sage will use its predictive modeling technology with H3's data to find associations between genomic alterations and pharmacologic drug responses; the two companies will also freely share the data and tools from the project with other organizations involved in cancer research 12/20/12 ImmunoGen Inc. (Waltham, Mass.) Amgen Inc.(Thousand Oaks, Calif.) $70 Licensing agreement for the exclusive right to use its maytansinoid targeted antibody payload technology to develop cancer therapeutics for a third, undisclosed target Amgen licensed rights to two other cancer targets in 2009 and has two compounds in clinical testing under those licenses; for each license, ImmunoGen received $1M up front and is entitled to milestone payments potentially totaling $34M, plus royalties on product sales 12/20/12 MedImmune (Gaithersburg, Md.) Progenics Pharmaceuticals Inc. (Tarryton, N.Y.) ND Deal to license a preclinical program for Clostridium difficile MedImmune will investigate efficacy and safety of a set of investigational monoclonal antibodies targeting toxins that are significant to the disease 12/18/12 MorphoSys AG (Martinsried, Germany) Bio-Rad Laboratories Inc.(Hercules, Calif.) $69.7 Sale of MorphoSys' Abd Serotec unit focused on research and diagnostic antibodies MorphoSys will receive €53M ($69.7M) in cash for the unit, and the transaction is expected to close in January 2013, with 130 employees transferring over to Bio-Rad 12/18/12 Open Monoclonal Technology Inc.(Palo Alto, Calif.) Crystal Bioscience Inc.(Emeryville, Calif.) ND Strategic alliance allowing OMT to use Crystal's antibody screening technology for its Gel-Encapslated Microenvironment antibody screening platform The technology is designed to identify all antibodies of a specific target across large populations of lymphocytes 12/5/12 Single Cell Technology Inc.(San Jose, Calif.) Open Monoclonal Technology Inc. (Palo Alto, Calif.) ND Collaboration allowing OMT to use its OmniRat transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT, and SCT will use its platform to massively screen plasma cells, measure the kinetics of secreted antibodies and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing SCT will advance and partner the program and share the economics with OMT, depending on the stage of development. SCT also will have an option to develop and commercialize selected products resulting from the research 12/4/12 Sutro Biopharma Inc. (South San Francisco) Celgene Corp. (Summit, N.J.) $500 $500M deal includes two undisclosed targets against which antibody conjugates and bispecific antibodies will be deployed, plus the manufacturing of a Celgene-owned antibody The deal brings a "substantial" up-front amount and includes milestone payments for Sutro as the companies will design and develop antibody-drug conjugates (ADCs) and bispecific antibodies for two targets, using Sutro's cell-free protein synthesis technology 12/19/12 uniQure BV (Amsterdam, the Netherlands) Benitec Biopharma Ltd.(Melbourne, Australia) ND Nonexclusive cross-licensing deal which gives uniQure access to Benitec's DNA-directed RNA interference (ddRNAi) technology in Huntington's disease uniQure granted Benitec nonexclusive access to its AAV5 delivery technology for the development of a ddRNAi therapy for hepatitis B 12/6/12 Ventria Bioscience Inc.(Fort Collins, Colo.) Meristem Therapeutics (Paris) ND Agreement under which Ventria will acquire portions of the intellectual property portfolio relating to recombinant lactoferrin developed by Meristem Ventria gains exclusive, royalty-free ownership rights for specific patents, including those related to recombinant human lactoferrin, in exchange for a one-time payment 12/4/12 YM BioSciences Inc. (Mississauga, Ontario) InnoKeys PTE Ltd. (Singapore) $2 YM sold assets related to nimotuzumab to InnoKeys InnoKeys paid $2M immediately plus undisclosed additional consideration 12/5/12 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found.

* The total value represents the amount of disclosed money involving collaborations between biotechnology companies, including manufacturing, marketing and distribution agreements detailed in the following chart.

** Denotes the date the item ran in BioWorld International.

(c) 2012 AHC Media LLC. All Rights Reserved.

[ Back To Technology News's Homepage ]